Literature DB >> 10970061

Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.

J J Ferreira1, O Rascol.   

Abstract

Levodopa-induced dyskinesias represent a major shortcoming of Parkinson's disease management, and its pharmacological treatment is generally unsatisfactory. However, the conclusive demonstration of the benefits associated with early prescription of a dopamine agonist, the antidyskinetic properties of 'old' antiparkinsonian compounds such as amantadine, and the striking results of functional stereotatic neurosurgery are extremely important advances for the treatment of levodopa-induced dyskinesias.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10970061     DOI： 10.1097/00019052-200008000-00011

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN： 1350-7540            Impact factor:   5.710


  5 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  [Temporary suppression of tremor by remifentanil in a patient with Parkinson's disease during cataract extraction under local anesthesia].

Authors:  W Böhmdorfer; Ph Schwarzinger; S Binder; P Sporn
Journal:  Anaesthesist       Date:  2003-09       Impact factor: 1.041

3.  Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

Authors:  O K Sujith; Carol Lane
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

4.  Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia.

Authors:  Myriam Heiman; Adrian Heilbut; Veronica Francardo; Ruth Kulicke; Robert J Fenster; Eric D Kolaczyk; Jill P Mesirov; Dalton J Surmeier; M Angela Cenci; Paul Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-05       Impact factor: 11.205

5.  Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.

Authors:  Anne Michel; Patrick Downey; Xavier Van Damme; Catherine De Wolf; Rainer Schwarting; Dieter Scheller
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.